Medpace Q2 2026 slides: bookings surge 28%, guidance raised

Medpace (MEDP) reported Q2 2026 revenue of $707.3M (+17.2% YoY) and diluted EPS of $4.25 (+37.1% YoY), topping consensus by 2.41% (revenue) and 6.78% (EPS). Net new business awards rose 28.2% to $795.7M (book-to-bill 1.13x) while EBITDA increased 17.6% to $153.4M with margin stable at 21.7%. The company raised full-year 2026 guidance to revenue of $2.805B–$2.885B (+10.9%–14.0%) and EBITDA of $618M–$642M, and repurchased $294.7M of shares in Q2; shares were up ~17.8% after hours.

Analysis

MEDP is one of the cleaner ways to express a rebound in small-cap biotech spending, but the real significance is balance-sheet optionality plus operating leverage: customer advances and negative working capital mean incremental growth converts to cash faster than the market usually models. That supports a higher quality multiple than a typical services name, especially if buybacks stay aggressive and consensus has to lift per-share numbers rather than just revenue.

The less obvious risk is concentration. When the top customer set becomes more important and bookings skew toward a narrow therapeutic mix, the stock can look like a compounder right until one funding window closes. If cardiometabolic demand is soft while oncology carries the quarter, MEDP is benefiting from portfolio rotation, not broad-based secular demand; that makes the next 1-2 quarters more dependent on sponsor financing than on internal execution.

For the group, this is a constructive read-through for outsourced development demand, but not all CROs are equal. Names with better small-biopharma exposure and less leverage to large-pharma deferrals should see estimate support; weaker operators could lag if pricing turns or if the market starts asking whether above-normal backlog conversion is partly pull-forward. The main catalyst path is 1-3 months of analyst revisions and booking commentary; the main falsifier is any slip back below 1.0x book-to-bill or a guide reset if biotech funding tightens.

Key Decisions for Investors

• Buy MEDP on a post-gap consolidation rather than chasing the first print; use the first 2-4% pullback to build a position for a 1-3 month target of another 8-12% as estimates move up.
• Pair trade: long MEDP / short ICLR for 1-3 months to express relative outperformance from stronger small-biotech sensitivity and better operating leverage; cut the short if ICLR shows similar booking acceleration.
• For defined risk, buy MEDP Jan-2027 call spreads on weakness after the initial move; the thesis works if the market starts capitalizing sustained high-single-digit growth plus buybacks, but risk is capped if bookings normalize.
• Watch XBI as the macro tell for MEDP exposure to biotech funding; if XBI rolls over for several weeks, reduce MEDP exposure because the stock's key support is sponsor capital availability, not just company execution.
• Set a hard risk trigger on fundamentals: if next quarter book-to-bill falls below 1.0x or management reduces full-year guide, treat the thesis as broken and de-risk immediately.